Benzinga·2025-12-16 13:30分组1 - Two stocks in the health care sector are signaling potential warnings for momentum-focused investors as of December 16, 2025 [1] - The Relative Strength Index (RSI) is a key momentum indicator, with values above 70 indicating that a stock may be overbought [2] - Avidity Biosciences reported quarterly losses of $1.27 per share, missing the analyst consensus estimate of $1.11, but its quarterly sales of $12.475 million exceeded expectations of $1.932 million [5] - Avidity's stock has increased approximately 141% over the past six months, with a 52-week high of $71.90, and currently has an RSI value of 76 [5] - Henry Schein's stock has gained around 6% over the past five days, reaching a 52-week high of $82.49, with an RSI value of 71.1 [5] 分组2 - Avidity Biosciences has entered into a merger agreement with Novartis, which is expected to enhance value for investors and expand its neuroscience pipeline [5] - Barclays analyst initiated coverage on Henry Schein with an Overweight rating and a price target of $86 [5] - Avidity's stock closed at $71.86, while Henry Schein's shares closed at $77.39 on the same day [5]